Highlight (Bioncotech)

Bridging the innate to adaptive immune response

Highlight (ex Bioncotech) is a clinical-stage, immune-oncology company focused on developing a cutting-edge RNA-based therapies against validated and novel targets in cancer and immune cells.

CEO  Marisol Quintero

Advent Contact  Shahzad Malik

Private Companies
14 April 2022 in Highlight Therapeutics, Press Release, Private Companies

Highlight Therapeutics announces follow-up results from Phase 2b study of BO-112 + anti-PD1 in confirmed anti-PD1 progressor melanoma patients at AACR

Press Release.   BO-112 demonstrates potential as new and highly effective second line therapy for melanoma BO-112 demonstrates potential as best-in-class therapy to overcome anti-PD1 resistance in melanoma patients whose…
Read More
15 March 2022 in Highlight Therapeutics, Press Release, Private Companies

Highlight Therapeutics to present at the American Association for Cancer Research (AACR) Annual Meeting 2022

Press Release.   Final results of SPOTLIGHT203 phase 2 study demonstrate new approach to second line treatment for melanomaMadrid, Spain, 15 March, 2022 – Highlight Therapeutics, (“Highlight”), a clinical-stage biopharmaceutical…
Read More
2 December 2021 in Highlight Therapeutics, Press Release, Private Companies

Highlight Therapeutics & Cima announce positive results from pre-clinical study combining BO-112 + STING agonist published in Journal for ImmunoTherapy of Cancer

Press Release.   Intratumoral co-injection of BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy Pre-clinical study data follow publication of positive Phase 2 results of…
Read More
12 November 2021 in Highlight Therapeutics, Press Release, Private Companies

Highlight Therapeutics announces positive preliminary results from Phase 2b study of BO-112 + anti-PD1 in confirmed anti-PD1 progressor melanoma patients at SITC

Press Release.   Highlight Therapeutics announces positive preliminary results from Phase 2b study of BO-112 + anti-PD1 in confirmed anti-PD1 progressor melanoma patients at SITC Breakthrough cancer treatment shows best-in-class…
Read More